期刊文献+

综合治疗时代晚期肝癌治疗的全局观 被引量:7

Holistic view of managing advanced liver cancer in the era of comprehensive treatment
下载PDF
导出
摘要 晚期肝癌严重威胁我国人民的生命和健康。肝脏的解剖结构及生理功能决定了肝癌具有天然的化疗耐药的特点。目前已有多种靶向治疗药物获批用于晚期肝癌的一线和二线治疗。免疫治疗的出现使肝癌的治疗进入新的时代。靶向与免疫治疗药物在机制上具有协同作用,而且二者的联合使用已在临床上使更多的晚期肝癌病人获益。同时,在靶向联合免疫的全身治疗基础上加用恰当的局部治疗,使部分病人获得了更长的生存期甚至治愈的机会。这种全身治疗联合局部治疗的综合治疗理念已被广泛接受。由于晚期肝癌病人的身体一般状况、肝脏基础疾病状态不同,为了使每个病人获得最大的临床获益,应该在综合治疗理念下,根据病人的具体情况个体化地定制治疗方案,并在多学科诊疗模式下对病人进行全程管理。 Advanced liver cancer is a serious threat and a heavy disease burden in our country.The anatomical structures and physiological functions of liver determine that liver cancer has the characteristics of natural chemotherapeutic resistance.Currently a variety of targeted therapies have been approved for first/second-line treatment of advanced liver cancer.The emergence of immunotherapy has brought the treatment of liver cancer into a new era.Targeted and immunotherapy drugs have a synergistic effect in mechanism and the combined use of both has shown great benefits.At the same time,some patients may achieve a longer survival and even a chance of cure by taking appropriate local treatments plus systemic targeted therapy and immunotherapy.This comprehensive treatment concept of systemic therapy plus local therapy has been widely accepted.Due to different physical status and basic liver diseases of patients with advanced liver cancer,for maximizing the clinical benefits,treatment plans should be customized according to the specific patient conditions under the comprehensive treatment concept.And patients should be managed throughout by a multi-disciplinary treatment mode.
作者 万雪帅 杜顺达 毛一雷 Wan Xueshuai;Du Shunda;Mao Yilei(Department of Liver Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)
出处 《腹部外科》 2021年第2期92-97,100,共7页 Journal of Abdominal Surgery
基金 陈孝平肝胆胰恶性肿瘤研究基金(CXPJJH11900001-2019215) 国家自然科学基金(81972698)。
关键词 晚期肝癌 综合治疗 免疫治疗 Advanced liver cancer Comprehensive treatment Immunotherapy
  • 相关文献

参考文献4

二级参考文献18

  • 1Zhao-You Tang,Xin-Da Zhou, Zeng-Chen Ma, Zhi-Quan Wu, Jia Fan, Lun-Xiu Qin and Yao Yu Shanghai, China Liver Cancer Institute & Zhongshan Hospital, Fudan University, Shanghai 200032 , China.Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2004,3(4):495-498. 被引量:18
  • 2林金芳,孙翠翔,郑怀美.Gonadotropin releasing hormone agonists and laparoscopy in the treatment of adenomyosis with infertility[J].Chinese Medical Journal,2000(5):58-61. 被引量:7
  • 3Funda Meric MD,Yehuda Z. Patt MD,Steve A. Curley MD,Judy Chase PharmD,Mark S. Roh MD,J. Nicolas Vauthey MD,Lee M. Ellis MD.Surgery After Downstaging of Unresectable Hepatic Tumors With Intra-Arterial Chemotherapy[J]. Annals of Surgical Oncology . 2000 (7)
  • 4Zhao-You Tang M.D.,Ye-Qin Yu M.D.,Xin-Da Zhou M.D.,Zeng-Chen MA M.D.,Ji-Zheu Lu M.D.,Zhi-Ying Lin M.D.,Kang-Da Liu M.D.,Sheng-Long Ye M.D.,Bing-Hui Yang M.D.,Hong-Wei Wang M.D.,Hui-Chuan Sun M.D..Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: Evaluation with analysis of 72 patients[J]. World Journal of Surgery . 1995 (6)
  • 5Zhao-You Tang M.D.,Ye-Qin Yu M.D.,Xin-Da Zhou M.D.,Zeng-Chen Ma M.D.,Bing-Hui Yang M.D.,Zhi-Ying Lin M.D.,Ji-Zhen Lu M.D.,Kang-Da Liu M.D.,Zeng Fan M.D.,Zhao-Chong Zeng M.D..Treatment of unresectable primary liver cancer: With reference to cytoreduction and sequential resection[J]. World Journal of Surgery . 1995 (1)
  • 6Brans B,De Winter F,Defreyne L,Troisi R,Vanlangenhove P,Van Vlierberghe H, et al.The anti-tumoral activity of neo- adjuvant intra-arterial 131 I-lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biotherapy and Radiopharmaceuticals . 2001
  • 7Majno PE,Adam R,Bismuth H,Castaing D,Ariche A,Krissat J, et al.Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepato- cellular carcinoma in patients with cirrhosis. Annals of Surgery . 1997
  • 8Patt YZ,Hassan MM,Lozano RD,Brown TD,Vauthey JN,Curley SA, et al.Phase II trial of systemic continuous fluorou- racil and subcutaneous recombinant interferon Alfa-2b for treat- ment of hepatocellular carcinoma. Journal of Clinical Oncology . 2003
  • 9Sitzmann JV,Abrams R.Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Annals of Surgery . 1993
  • 10Tang ZY,Yu YQ.Long-term survival of hepatocellular carci- noma with reference to the role of early resection, multiopera- tion and multimodality treatment. Gann Monograph on Cancer Research . 1986

共引文献615

同被引文献85

引证文献7

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部